Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.
about
Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis.Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs
P2860
Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Presynaptic Dopamine Capacity ...... apine: An [18F]DOPA PET Study.
@en
Presynaptic Dopamine Capacity ...... apine: An [18F]DOPA PET Study.
@nl
type
label
Presynaptic Dopamine Capacity ...... apine: An [18F]DOPA PET Study.
@en
Presynaptic Dopamine Capacity ...... apine: An [18F]DOPA PET Study.
@nl
prefLabel
Presynaptic Dopamine Capacity ...... apine: An [18F]DOPA PET Study.
@en
Presynaptic Dopamine Capacity ...... apine: An [18F]DOPA PET Study.
@nl
P2093
P2860
P50
P356
P1476
Presynaptic Dopamine Capacity ...... apine: An [18F]DOPA PET Study.
@en
P2093
Euitae Kim
Jae Sung Lee
Jin Woo Park
Jun Soo Kwon
Oliver D Howes
Seongho Seo
P2860
P2888
P304
P356
10.1038/NPP.2016.258
P407
P577
2016-11-18T00:00:00Z